Mazor Robotics Ltd. (NASDAQ:MZOR) has received an average rating of “Hold” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $37.33.

Several equities research analysts have recently commented on MZOR shares. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $46.00 price target on shares of Mazor Robotics in a research note on Monday, June 12th. Zacks Investment Research upgraded Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 price target for the company in a research note on Tuesday, August 15th. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics in a research note on Wednesday, August 30th. ValuEngine upgraded Mazor Robotics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, B. Riley restated a “neutral” rating and set a $31.00 price target on shares of Mazor Robotics in a research note on Monday, May 15th.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/10/mazor-robotics-ltd-mzor-receives-37-33-average-pt-from-brokerages.html.

Several institutional investors have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new stake in shares of Mazor Robotics during the second quarter worth approximately $2,421,000. Raymond James Financial Services Advisors Inc. purchased a new position in Mazor Robotics in the second quarter worth $770,000. Royal Bank of Canada raised its position in Mazor Robotics by 9.2% in the second quarter. Royal Bank of Canada now owns 21,663 shares of the medical instruments supplier’s stock worth $749,000 after acquiring an additional 1,819 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 641 shares in the last quarter. Finally, Messner & Smith Theme Value Investment Management Ltd. CA raised its position in Mazor Robotics by 23.6% in the second quarter. Messner & Smith Theme Value Investment Management Ltd. CA now owns 36,201 shares of the medical instruments supplier’s stock worth $1,252,000 after acquiring an additional 6,919 shares in the last quarter. Institutional investors and hedge funds own 27.52% of the company’s stock.

Shares of Mazor Robotics (NASDAQ MZOR) traded down 4.30% during trading on Tuesday, hitting $44.11. 459,712 shares of the company traded hands. The stock’s market capitalization is $1.06 billion. Mazor Robotics has a 52-week low of $20.19 and a 52-week high of $49.64. The company has a 50-day moving average of $40.10 and a 200-day moving average of $34.91.

Mazor Robotics (NASDAQ:MZOR) last issued its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The company had revenue of $15.46 million during the quarter, compared to analysts’ expectations of $15.38 million. During the same quarter in the previous year, the business earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 86.7% on a year-over-year basis. Equities analysts expect that Mazor Robotics will post ($0.74) EPS for the current year.

About Mazor Robotics

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.